Mascha Binder

This paper explores using anti-TSHR autoantibodies to create bispecific antibodies and CAR T cells for treating poorly differentiated thyroid cancer, showing potent in vitro and in vivo activity.

Desialylation enhances bispecific T cell engager responses by relieving a sialoglycan-dependent restraint in human T cells.

This study profiles tumor-reactive T cell dynamics during TIL therapy in metastatic melanoma, identifying factors associated with response and resistance.

This study develops bispecific antibodies targeting IGLV3-21R110 to selectively kill high-risk CLL cells while sparing healthy B cells and stem cells.

The paper identifies CD39+ tumor-associated NK cells as a cytotoxic effector state in NSCLC responsive to NKG2A blockade through multiomic analysis.

The paper identifies Tmem127 as a regulator of T cell homeostasis by controlling IL-7 receptor surface expression and common gamma chain interactions.

The paper evaluates five PHB-targeting molecules in B cell lymphoma models, showing varied antiproliferative and cytotoxic effects across different cell lines.

This study develops a fully human CAR-T cell therapy targeting the STn antigen, showing activity in preclinical models of gastro-intestinal and gynecological cancers.

This study identifies the transcriptional profile of circulating autoreactive CD4 T cells in autoimmune liver diseases and shows their functional relationship to liver-specific pathogenic clones.

This study compares viral and non-viral methods for CAR T cell engineering, finding that non-viral SB transposition alters T cell activation and co-inhibition markers, with CAR design and donor type influencing outcomes.

This paper uses machine learning to classify B cell lymphomas based on BCR repertoire sequencing, achieving high accuracy in distinguishing between subtypes.

This study develops CAR T cells targeting a specific mutation in CLL to selectively kill cancer cells while sparing healthy B cells.